Adicet Bio CSO granted 55,000 stock options

Adicet Bio, Inc. reported that Chief Scientific Officer Blake Aftab received a grant of stock options covering 55,000 shares of common stock.

Rhea-AI Filing Summary

Adicet Bio, Inc. reported that Chief Scientific Officer Blake Aftab received a grant of stock options covering 55,000 shares of common stock. The options have an exercise price of $8.10 per share and expire on June 18, 2036.

These options were granted as compensation and are structured to vest over time. One forty-eighth of the options vests on each of the 48 monthly anniversaries of the grant date, with partial acceleration tied to certain performance milestones, as long as Aftab continues his service relationship with the company.

Insider Trade Summary

Grant/Award: 55,000 shares

Grant/Award 1 txn

Insider Aftab Blake

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	55,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 55,000 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

Key Figures

Options granted: 55,000 options Exercise price: $8.10 per share Expiration date: June 18, 2036 +1 more

4 metrics

Options granted 55,000 options Stock Option (Right to Buy) granted to CSO

Exercise price $8.10 per share Conversion or exercise price of options

Expiration date June 18, 2036 Option expiration

Post-grant option holdings 55,000 options Total derivative securities following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, performance milestones

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 8.1000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

performance milestones financial

"with partial acceleration tied to certain performance milestones"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Adicet Bio (ACET) report for Blake Aftab?

Adicet Bio reported a grant of stock options to Chief Scientific Officer Blake Aftab for 55,000 shares of common stock. This is a compensation award, not an open-market purchase or sale, and gives him the right to buy shares at a fixed price.

What is the exercise price of Blake Aftab’s new Adicet Bio stock options?

The granted stock options have an exercise price of $8.10 per share. This means Aftab can purchase Adicet Bio common stock at $8.10 if the options vest and are exercised before expiration, regardless of the market price at that time.

How do Blake Aftab’s Adicet Bio stock options vest over time?

One forty-eighth of the 55,000 stock options vests on each of the next 48 monthly anniversaries of the grant date. Vesting also includes partial acceleration tied to certain performance milestones, contingent on Aftab maintaining a service relationship with Adicet Bio.

When do Blake Aftab’s Adicet Bio stock options expire?

The stock options granted to Blake Aftab expire on June 18, 2036. If they are not exercised by that date, the right to purchase Adicet Bio common stock at the $8.10 exercise price will lapse and the options will become worthless.

Did Blake Aftab buy or sell Adicet Bio shares in this Form 4 filing?

This Form 4 reflects a grant of stock options to Blake Aftab, not a market buy or sell of Adicet Bio shares. It records a compensation-related acquisition of derivative securities rather than trading of common stock in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 06:49 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aftab Blake

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.1	06/19/2026		A		55,000		(1)	06/18/2036	Common Stock	55,000	$0	55,000	D

Explanation of Responses:

1. 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date with partial acceleration tied to certain performance milestones, provided that the Reporting Person maintains a service relationship with the Issuer as of the applicable vesting dates.

	/s/ Nick Harvey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)